Sanofi Aktie
| 91,12EUR | -0,68EUR | -0,74% |
WKN: 920657 / ISIN: FR0000120578
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 89,40 |
| L'Oréal SA | 9,32 |
| Government Pension Fund - Global (The) | 2,26 |
| Dodge & Cox | 1,77 |
| Sanofi | 1,28 |
| Vanguard Total International Stock Index Fund | 1,21 |
| Dodge & Cox International Stock Fund | 1,17 |
| Vanguard Developed Markets Index Fund | 0,75 |
| Capital Income Builder | 0,64 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 100 409 | 99 412 | 95 442 | 91 573 | 87 994 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,36 | 0,36 | 0,40 | 0,47 | 0,49 |
Bilanz (in Mio. EUR) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 28 611 | 33 703 | 30 564 | 34 026 | 30 655 |
| Summe Anlagevermögen | 84 125 | 80 826 | 89 678 | 92 696 | 95 809 |
| Summe Aktiva | 112 736 | 114 529 | 120 242 | 126 722 | 126 464 |
Bilanz (in Mio. EUR) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 53 628 | 51 382 | 51 211 | 51 570 | 52 111 |
| Summe Eigenkapital | 59 108 | 63 147 | 69 031 | 75 152 | 74 353 |
| Summe Passiva | 112 736 | 114 529 | 120 242 | 126 722 | 126 464 |
Adresse
| 46, avenue de la Grande Armée, 75017 Paris | |
| Telefon | +33 (1) 53-77-40-00 |
| Fax | +33 (1) 53-77-44-03 |
| Internet | http://www.sanofi.com |
Management
|
Alexandra Roger
Head-Legal Corporate & Finance |
|
Anne-Francoise Nesmes
Independent Non-Executive Director |
|
Antoine Yver
Independent Director |
|
Arnaud Delépine
Investor Relations Contact |
|
Audrey Duval Derveloy
Executive Vice President & Head-Corporate Affairs |
|
Barbara Lavernos
Independent Director |
|
Brendan OCallaghan
exec Vice President-Global Manufacturing & Supply |
|
Carole Gabriella Ferrand
Independent Director |
|
Christophe Babule
Non-Independent Director |
|
Clotilde Delbos
Independent Director |
|
Dietmar P. Berger
Chief Medical Officer & Global Head-Development |
|
Emile Voest
Independent Director |
|
Emmanuel Frenehard
Chief Digital Officer & Executive Vice President |
|
Fabienne Lecorvaisier
Independent Director |
|
François-Xavier Michel Marie Roger
Chief Financial Officer |
|
Frédéric Oudéa
Independent Chairman |
|
Gilles Schnepp
Independent Director |
|
Houman Ashrafian
Executive VP, Head-Research & Development |
|
John Sundy
Independent Director |
|
Julie van Ongevalle
Executive Vice President-Consumer Healthcare |
|
Lise Kingo
Independent Director |
|
Madeleine Roach
Executive Vice President-Business Operations |
|
Natalie Bickford
Chief People Officer & Executive Vice President |
|
Nestle Frank
Chief Scientific Officer & Global Head-Research |
|
Olivier Antoine M. Charmeil
Executive Vice President-General Medicines |
|
Patrick Kron
Independent Director |
|
Paul Hudson
Chief Executive Officer & Director |
|
Preethi Sundaram
Director-Global Clinical Research |
|
Rachel Duan
Independent Director |
|
Raj Verma
Chief Diversity, Culture & Experience Officer |
|
Roy Papatheodorou
Executive Vice President & General Counsel |
|
Thomas Kudsk Larsen
Head-Investor Relations |
|
Wolfgang Laux
Non-Independent Director |
|
Yann Tran
Non-Independent Director |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
